Fortitude Biomedicines enters the degradation race with catalytic ADC platform GLUE-DACTM
Fortitude Biomedicines launches with $13M to develop glue-payload ADCs for autoimmune and cancer treatment. Find out what makes this platform different.
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
Can Enodia’s SEC61-targeting platform redefine druggability in secreted and membrane proteins?
Enodia Therapeutics raised €20.7M to advance AI-powered small molecules targeting SEC61 for selective protein degradation. Find out what this could change.
Amgen acquires Dark Blue Therapeutics to expand targeted AML degradation strategy
Amgen has acquired United Kingdom-based Dark Blue Therapeutics Ltd. in a deal valued at up to $840 million, adding a first-in-class preclinical asset to its early oncology pipeline. The investigational small molecule, designed to degrade MLLT1 and MLLT3 proteins, targets transcriptional dependencies in acute myeloid leukemia. With preclinical data suggesting anti-leukemic activity and mechanistic differentiation, […]
Beyond biologics: Can structure-guided small molecules replace antibodies in intracellular targets?
For much of the past two decades, monoclonal antibodies have dominated modern drug development. Their ability to bind with high specificity, block protein function, and engage immune mechanisms has transformed the treatment of cancer, autoimmune disorders, and infectious disease. But despite their blockbuster status, biologics have a blind spot. They are largely excluded from the […]